FORT LAUDERDALE, Fla., Sept. 1 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), a leader in integrated electronic data capture (EDC) solutions for clinical trials, and one of the fastest growing companies in the EDC marketplace, announced today that three additional clinical research organizations (CRO) have joined its rapidly expanding partnership program, the CRO Preferred Program. The partnership allows CROs in the program to offer their clients the flexible, intuitive and robust EDC solution, TrialMaster(TM), for clinical trials. The CRO Preferred Program's distinct advantages include fixed pricing with no hidden fees, complete sales and marketing support from OmniComm, a dedicated hosted environment and comprehensive training and support for TrialMaster.
"Our CRO Preferred program continues to expand both domestically and internationally and we now have close to 40 CRO partners. We are pleased to have added the eClinical Consulting Group, MakroCare and Symbiance to this already very successful program. CROs and their customers are realizing the substantial benefits, such as the fixed pricing and world class hosting services that other vendors just do not offer. Partnering with OmniComm allows CROs to offer their customers a first class EDC product and gives them a competitive edge in the bidding process," said Stephen Johnson, COO of OmniComm. "It's a win for everyone involved, the CRO, OmniComm and most importantly the clients that we serve."
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and Russia as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT: Catherine Lemercier Gary Nash OmniComm Systems, Inc. CEOcast, Inc. for OmniComm 954-473-1254 Extension 283 212-732-4300 email@example.com firstname.lastname@example.org Stephen Johnson at: + 1 954-377-1726
|SOURCE OmniComm Systems, Inc.|
Copyright©2009 PR Newswire.
All rights reserved